# How long did growth hormone and IGF-1 change in early human trials?

- Article ID: research-069
- Product: CJC-1295 With DAC (cjc-1295-with-dac-431, cjc-1295-with-dac-622, cjc-1295-with-dac-571)
- Canonical page: https://heritagebiolabs.com/research-library/articles/069-how-long-did-growth-hormone-and-igf-1-change-in-early-human-trials
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-with-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-431
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-622
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-571
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2005, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains built from amino acids and joined by peptide bonds. Some act like the natural signals that tell the pituitary gland to release a hormone. CJC-1295 With DAC is an investigational form of a growth hormone–releasing hormone (GHRH) analogue. Its attached drug affinity complex (DAC) allows it to bind to blood proteins. Early studies asked how long the circulating peptide and its effects could be measured in healthy adults. [1, 2]

No recent primary human trial measuring the duration of these responses was identified. The older direct evidence comes from two randomized, double-blind, placebo-controlled studies reported together by Teichman and colleagues. The team measured the study compound as well as growth hormone (GH) and insulin-like growth factor 1 (IGF-1), a downstream signal that responds to GH. The estimated half-life of the compound ranged from 5.8 to 8.1 days across the estimates reported. Mean GH concentrations remained elevated for at least six days after one exposure, and mean IGF-1 concentrations rose for about nine to eleven days. [1]

A half-life describes how long it takes the measured concentration to fall by half in the relevant part of its decline. It is different from the time a downstream hormone stays elevated. The researchers' separate measurements make it possible to see that difference. Their placebo comparisons help isolate the short-term endocrine effects within the study design. [1]

The endpoints were blood concentrations in healthy adults. They did not establish that a persistent increase would improve growth, physical function, or any other patient outcome. The published studies were brief and reported no serious adverse reactions, while the FDA's later assessment noted reactions including flushing, headache, and injection-site symptoms. Longer observation and studies in defined patient populations would be needed to describe the clinical effects and risks. [1, 2]

## Sources

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism (publication 2005-12-13). <https://pubmed.ncbi.nlm.nih.gov/16352683/>
2. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 014 - CJC-1295 No DAC and CJC-1295 With DAC.docx; article 69; content SHA-256 8ed5d5aa2a6ac889f40f9c5e63cb9f503051891e0c2fd967e052bc5b70d7d965.
